{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:01:58Z","timestamp":1785186118073,"version":"3.55.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40259-024-00694-x","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T06:26:39Z","timestamp":1733552799000},"page":"21-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Investigational RNA Interference Agents for Hepatitis B"],"prefix":"10.1007","volume":"39","author":[{"given":"Rex Wan-Hin","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lung-Yi","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,7]]},"reference":[{"key":"694_CR1","unstructured":"The CDA Foundation. Polaris Dashboard. 2024 [cited 2024 8 November]. https:\/\/cdafound.org\/polaris\/dashboard\/"},{"issue":"5","key":"694_CR2","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1097\/HEP.0000000000000431","volume":"78","author":"MG Ghany","year":"2023","unstructured":"Ghany MG, Buti M, Lampertico P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. Hepatology. 2023;78(5):1654\u201373.","journal-title":"Hepatology"},{"issue":"7","key":"694_CR3","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/jvh.13095","volume":"26","author":"LY Mak","year":"2019","unstructured":"Mak LY, Seto WK, Hui RW, et al. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. J Viral Hepatitis. 2019;26(7):818\u201327.","journal-title":"J Viral Hepatitis"},{"issue":"2","key":"694_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3350\/cmh.2022.0399","volume":"29","author":"RW Hui","year":"2022","unstructured":"Hui RW, Mak LY, Cheung TT, et al. Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective. Clin Mol Hepatol. 2022;29(2):217\u201329 (ePub ahead of print).","journal-title":"Clin Mol Hepatol"},{"key":"694_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16728","author":"LY Mak","year":"2024","unstructured":"Mak LY, Hui RW, Chung MSH, et al. Regression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum enhanced liver fibrosis test. J Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1111\/jgh.16728.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"694_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3350\/cmh.2022.0448","volume":"29","author":"LY Mak","year":"2023","unstructured":"Mak LY, Hui RW, Fung J, et al. The role of different viral biomarkers on the management of chronic hepatitis B. Clin Mol Hepatol. 2023;29(2):263\u201376.","journal-title":"Clin Mol Hepatol"},{"issue":"10161","key":"694_CR7","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"WK Seto","year":"2018","unstructured":"Seto WK, Lo YR, Pawlotsky JM, et al. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313\u201324.","journal-title":"Lancet"},{"issue":"2","key":"694_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/14728214.2022.2074977","volume":"27","author":"RW Hui","year":"2022","unstructured":"Hui RW, Mak LY, Seto WK, et al. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials. Expert Opin Emerg Drugs. 2022;27(2):127\u201340.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"694_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa2213429","volume":"389","author":"H Wedemeyer","year":"2023","unstructured":"Wedemeyer H, Aleman S, Brunetto MR, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389(1):22\u201332.","journal-title":"N Engl J Med"},{"issue":"12","key":"694_CR10","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/jvh.13608","volume":"28","author":"R Erken","year":"2021","unstructured":"Erken R, Andre P, Roy E, et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: a safety study. J Viral Hepat. 2021;28(12):1690\u20138.","journal-title":"J Viral Hepat"},{"key":"694_CR11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3350\/cmh.2022.0012","volume":"28","author":"RW Hui","year":"2022","unstructured":"Hui RW, Mak LY, Seto WK, et al. RNA interference as a novel treatment strategy for chronic hepatitis B infection. Clin Mol Hepatol. 2022;28:408\u201324.","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"694_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11901-020-00523-z","volume":"19","author":"RW Hui","year":"2020","unstructured":"Hui RW, Mak LY, Seto WK, et al. Role of core\/capsid inhibitors in functional cure strategies for chronic hepatitis B. Curr Hepat Rep. 2020;19(3):293\u2013301.","journal-title":"Curr Hepat Rep."},{"issue":"8","key":"694_CR13","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","volume":"158","author":"M Bazinet","year":"2020","unstructured":"Bazinet M, P\u00e2ntea V, Placinta G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection na\u00efve to nucleos(t)ide therapy. Gastroenterology. 2020;158(8):2180\u201394.","journal-title":"Gastroenterology"},{"issue":"3","key":"694_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.jhep.2022.09.027","volume":"78","author":"EJ Gane","year":"2023","unstructured":"Gane EJ, Dunbar PR, Brooks AE, et al. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression. J Hepatol. 2023;78(3):513\u201323.","journal-title":"J Hepatol"},{"key":"694_CR15","unstructured":"Wang G, Cui Y, Hu G, et al. HBsAg loss in chronic hepatitis B patients after 24-week treatment with subcutaneously administered PD-L1 antibody ASC22 (Envafolimab): interim results from a phase IIb extension cohort. In: The Liver Meeting, 2023; Boston, US2023."},{"issue":"6","key":"694_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100361","volume":"3","author":"H Ma","year":"2021","unstructured":"Ma H, Lim TH, Leerapun A, et al. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study. JHEP Rep. 2021;3(6): 100361.","journal-title":"JHEP Rep."},{"key":"694_CR17","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.1002\/hep.32426","volume":"76","author":"K Agarwal","year":"2022","unstructured":"Agarwal K, Yuen M-F, Wedemeyer H, et al. Reduction in hepatitis B viral DNA and hepatitis B surface antigen following administration of a single dose of VIR-3434, an investigational neutralizing monoclonal antibody: first experience in a population with viremia. Hepatology. 2022;76:S303\u20134.","journal-title":"Hepatology"},{"issue":"6669","key":"694_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806\u201311.","journal-title":"Nature"},{"issue":"6836","key":"694_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494\u20138.","journal-title":"Nature"},{"issue":"27","key":"694_CR20","doi-asserted-by":"publisher","first-page":"17897","DOI":"10.1074\/jbc.R900012200","volume":"284","author":"AJ Pratt","year":"2009","unstructured":"Pratt AJ, MacRae IJ. The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem. 2009;284(27):17897\u2013901.","journal-title":"J Biol Chem"},{"issue":"17","key":"694_CR21","doi-asserted-by":"publisher","first-page":"9742","DOI":"10.1073\/pnas.171251798","volume":"98","author":"NJ Caplen","year":"2001","unstructured":"Caplen NJ, Parrish S, Imani F, et al. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA. 2001;98(17):9742\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"694_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.molcel.2005.07.011","volume":"19","author":"YR Yuan","year":"2005","unstructured":"Yuan YR, Pei Y, Ma JB, et al. Crystal structure of A. aeolicus argonaute, a site-specific DNA-guided endoribonuclease, provides insights into RISC-mediated mRNA cleavage. Mol Cell. 2005;19(3):405\u201319.","journal-title":"Mol Cell"},{"issue":"4","key":"694_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nsmb918","volume":"12","author":"FV Rivas","year":"2005","unstructured":"Rivas FV, Tolia NH, Song JJ, et al. Purified Argonaute2 and an siRNA form recombinant human RISC. Nat Struct Mol Biol. 2005;12(4):340\u20139.","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"694_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.molcel.2006.01.031","volume":"21","author":"CP Petersen","year":"2006","unstructured":"Petersen CP, Bordeleau ME, Pelletier J, et al. Short RNAs repress translation after initiation in mammalian cells. Mol Cell. 2006;21(4):533\u201342.","journal-title":"Mol Cell"},{"issue":"2","key":"694_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/path.2993","volume":"226","author":"JK Watts","year":"2012","unstructured":"Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol. 2012;226(2):365\u201379.","journal-title":"J Pathol"},{"issue":"3","key":"694_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","volume":"28","author":"AD Springer","year":"2018","unstructured":"Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28(3):109\u201318.","journal-title":"Nucleic Acid Ther"},{"issue":"Pt 8","key":"694_CR27","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1242\/jcs.066399","volume":"123","author":"M Dominska","year":"2010","unstructured":"Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010;123(Pt 8):1183\u20139.","journal-title":"J Cell Sci"},{"issue":"9","key":"694_CR28","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1093\/nar\/gkz214","volume":"47","author":"E Linnane","year":"2019","unstructured":"Linnane E, Davey P, Zhang P, et al. Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines. Nucleic Acids Res. 2019;47(9):4375\u201392.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"694_CR29","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","volume":"25","author":"XH Liang","year":"2017","unstructured":"Liang XH, Sun H, Nichols JG, et al. RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther. 2017;25(9):2075\u201392.","journal-title":"Mol Ther"},{"issue":"6","key":"694_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421\u201346.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"694_CR31","first-page":"187","volume":"85","author":"K Gavrilov","year":"2012","unstructured":"Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012;85(2):187\u2013200.","journal-title":"Yale J Biol Med"},{"issue":"4","key":"694_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.101723","volume":"3","author":"EH Roh","year":"2022","unstructured":"Roh EH, Sullivan MO, Epps TH 3rd. A kinetic modeling platform for predicting the efficacy of siRNA formulations in vitro and in vivo. STAR Protoc. 2022;3(4): 101723.","journal-title":"STAR Protoc."},{"issue":"1","key":"694_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"694_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/17460441.2024.2306843","volume":"19","author":"V Plant\u00e9-Bordeneuve","year":"2024","unstructured":"Plant\u00e9-Bordeneuve V, Perrain V. Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy. Expert Opin Drug Discov. 2024;19(4):393\u2013402.","journal-title":"Expert Opin Drug Discov"},{"issue":"13","key":"694_CR35","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs SF, Frishberg Y, Hulton SA, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021;384(13):1216\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"694_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","volume":"11","author":"KK Ray","year":"2023","unstructured":"Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6896","key":"694_CR37","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nature00896","volume":"418","author":"JM Jacque","year":"2002","unstructured":"Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature. 2002;418(6896):435\u20138.","journal-title":"Nature"},{"issue":"9729","key":"694_CR38","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/S0140-6736(10)60357-1","volume":"375","author":"TW Geisbert","year":"2010","unstructured":"Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375(9729):1896\u2013905.","journal-title":"Lancet"},{"key":"694_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-2180-1-34","volume":"1","author":"V Bitko","year":"2001","unstructured":"Bitko V, Barik S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol. 2001;1:34.","journal-title":"BMC Microbiol"},{"issue":"2","key":"694_CR40","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1128\/JVI.79.2.1027-1035.2005","volume":"79","author":"L Gitlin","year":"2005","unstructured":"Gitlin L, Stone JK, Andino R. Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. J Virol. 2005;79(2):1027\u201335.","journal-title":"J Virol"},{"issue":"4","key":"694_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/v9040075","volume":"9","author":"T Tu","year":"2017","unstructured":"Tu T, Budzinska MA, Shackel NA, et al. HBV DNA integration: molecular mechanisms and clinical implications. Viruses. 2017;9(4):75.","journal-title":"Viruses"},{"issue":"4","key":"694_CR42","first-page":"842","volume":"38","author":"M Konishi","year":"2003","unstructured":"Konishi M, Wu CH, Wu GY. Inhibition of HBV replication by siRNA in a stable HBV-producing cell line. Hepatology. 2003;38(4):842\u201350.","journal-title":"Hepatology"},{"issue":"2","key":"694_CR43","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","volume":"159","author":"N Le Bert","year":"2020","unstructured":"Le Bert N, Gill US, Hong M, et al. Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection. Gastroenterology. 2020;159(2):652\u201364.","journal-title":"Gastroenterology"},{"issue":"3","key":"694_CR44","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1053\/j.gastro.2015.11.050","volume":"150","author":"JJ Park","year":"2016","unstructured":"Park JJ, Wong DK, Wahed AS, et al. Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology. 2016;150(3):684-695.e5.","journal-title":"Gastroenterology"},{"issue":"6","key":"694_CR45","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1053\/j.gastro.2020.01.032","volume":"158","author":"T Michler","year":"2020","unstructured":"Michler T, Kosinska AD, Festag J, et al. Knockdown of virus antigen expression increases therapeutic vaccine efficacy in high-titer hepatitis B virus carrier mice. Gastroenterology. 2020;158(6):1762-1775.e9.","journal-title":"Gastroenterology"},{"key":"694_CR46","doi-asserted-by":"crossref","first-page":"S761","DOI":"10.1016\/j.jhep.2021.06.039","volume":"75","author":"B Paratala","year":"2021","unstructured":"Paratala B, Park JJ, Ganchua SC, et al. Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers. J Hepatol. 2021;75:S761.","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"694_CR47","first-page":"S54","volume":"78","author":"P Lampertico","year":"2023","unstructured":"Lampertico P, Asselah T, Gane EJ, et al. Intrahepatic changes in viral and immune markers following treatment with JNJ-73763989 (JNJ-3989) and nucleos(t)ide analogs (NAs), in patients with chronic hepaititis B (CHB): INSIGHT Week 40 (W40) interim results. Hepatology. 2023;78(Suppl. 1):S54\u20135.","journal-title":"Hepatology"},{"issue":"5","key":"694_CR48","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/mt.2013.31","volume":"21","author":"CI Wooddell","year":"2013","unstructured":"Wooddell CI, Rozema DB, Hossbach M, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther. 2013;21(5):973\u201385.","journal-title":"Mol Ther"},{"key":"694_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0241","author":"CI Wooddell","year":"2017","unstructured":"Wooddell CI, Yuen MF, Chan HL, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aan0241.","journal-title":"Sci Transl Med."},{"key":"694_CR50","unstructured":"Yuen MF, Holmes J, Strasser SI, et al., editors. 48 weeks of AB-729 + nucleos(t)ide analogue (NA) therapy results in profound, sustained HBsAg declines in both HBeAg+ and HBeAg- subjects which are maintained in HBeAg- subjects who have discontinued all therapy. Global Hepatitis Summit; 2023; Paris, France."},{"issue":"5","key":"694_CR51","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jhep.2023.07.026","volume":"79","author":"EJ Gane","year":"2023","unstructured":"Gane EJ, Kim W, Lim TH, et al. First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection. J Hepatol. 2023;79(5):1139\u201349.","journal-title":"J Hepatol"},{"issue":"5","key":"694_CR52","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jhep.2022.07.010","volume":"77","author":"MF Yuen","year":"2022","unstructured":"Yuen MF, Locarnini S, Lim TH, et al. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol. 2022;77(5):1287\u201398.","journal-title":"J Hepatol"},{"key":"694_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-333026","author":"LY Mak","year":"2024","unstructured":"Mak LY, Wooddell CI, Lenz O, et al. Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989. Gut. 2024. https:\/\/doi.org\/10.1136\/gutjnl-2024-333026.","journal-title":"Gut"},{"issue":"4","key":"694_CR54","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jhep.2023.05.023","volume":"79","author":"E Gane","year":"2023","unstructured":"Gane E, Lim YS, Kim JB, et al. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: results from randomized clinical trials. J Hepatol. 2023;79(4):924\u201332.","journal-title":"J Hepatol"},{"issue":"S1","key":"694_CR55","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/S0168-8278(22)00537-2","volume":"77","author":"YS Lim","year":"2022","unstructured":"Lim YS, Yuen MF, Cloutier D, et al. Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection. J Hepatol. 2022;77(S1):S69\u201370.","journal-title":"J Hepatol"},{"issue":"S1","key":"694_CR56","doi-asserted-by":"publisher","first-page":"S1152","DOI":"10.1016\/S0168-8278(23)03287-7","volume":"78","author":"WK Seto","year":"2023","unstructured":"Seto WK, Liang Z, Gan LM, et al. Safety and antiviral activity of RBD1016, a RNAi therapeutic, in Chinese subjects with chronic hepatitis B virus (HBV) infection. J Hepatol. 2023;78(S1):S1152.","journal-title":"J Hepatol"},{"issue":"11","key":"694_CR57","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1080\/13543784.2023.2277389","volume":"32","author":"LY Mak","year":"2023","unstructured":"Mak LY, Hui RW, Fung J, et al. Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress. Expert Opin Investig Drugs. 2023;32(11):971\u201383.","journal-title":"Expert Opin Investig Drugs"},{"issue":"21","key":"694_CR58","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","volume":"387","author":"MF Yuen","year":"2022","unstructured":"Yuen MF, Lim SG, Plesniak R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection. N Engl J Med. 2022;387(21):1957\u201368.","journal-title":"N Engl J Med"},{"issue":"S1","key":"694_CR59","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/S0168-8278(23)00597-4","volume":"78","author":"A Gadano","year":"2023","unstructured":"Gadano A, Arbune M, Atsukawa M, et al. Evidence of durable response to bepirovirsen in B-clear responders: B-sure first annual report. J Hepatol. 2023;78(S1):S110\u20131.","journal-title":"J Hepatol"},{"issue":"4","key":"694_CR60","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jhep.2022.05.031","volume":"77","author":"MF Yuen","year":"2022","unstructured":"Yuen MF, Heo J, Kumada H, et al. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J Hepatol. 2022;77(4):967\u201377.","journal-title":"J Hepatol"},{"issue":"4","key":"694_CR61","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/hep.31920","volume":"74","author":"E Gane","year":"2021","unstructured":"Gane E, Yuen MF, Kim DJ, et al. Clinical study of single-stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B. Hepatology. 2021;74(4):1795\u2013808.","journal-title":"Hepatology"},{"issue":"S1","key":"694_CR62","doi-asserted-by":"publisher","first-page":"S824","DOI":"10.1016\/S0168-8278(22)01945-6","volume":"77","author":"EJ Gane","year":"2022","unstructured":"Gane EJ, Yuen MF, Schwabe C, et al. Safety, tolerability and pharmacokinetics of single ascending doses of ALG-020572, a GalNAc-conjugated antisense oligonucleotide, in healthy subjects. J Hepatol. 2022;77(S1):S824.","journal-title":"J Hepatol"},{"issue":"4","key":"694_CR63","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11901-022-00590-4","volume":"21","author":"RW Hui","year":"2022","unstructured":"Hui RW, Mak LY, Cheung KS, et al. Novel combination strategies with investigational agents for functional cure of chronic hepatitis B infection. Curr Hepat Rep. 2022;21(4):59\u201367.","journal-title":"Curr Hepat Rep."},{"issue":"S1","key":"694_CR64","first-page":"S47","volume":"78","author":"G Macquillan","year":"2023","unstructured":"Macquillan G, Elkhashab M, Antonov K, et al. Preliminary off- treatment responses following 48 weeks of vebicorvir, nucleos(t)ide reverse transcriptase inhibitor, and AB-729 combination in virologically suppressed patients with hepatitis B e antigen negative chronic hepatitis B: analysis from an open-label phase 2 study. Hepatology. 2023;78(S1):S47\u20138.","journal-title":"Hepatology"},{"issue":"9","key":"694_CR65","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"MF Yuen","year":"2023","unstructured":"Yuen MF, Asselah T, Jacobson IM, et al. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8(9):790\u2013802.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"694_CR66","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","volume":"81","author":"K Agarwal","year":"2024","unstructured":"Agarwal K, Buti M, van B\u00f6mmel F, et al. JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2. J Hepatol. 2024;81:404\u201314.","journal-title":"J Hepatol"},{"issue":"S1","key":"694_CR67","doi-asserted-by":"publisher","first-page":"S809","DOI":"10.1016\/S0168-8278(24)02236-0","volume":"80","author":"MF Yuen","year":"2024","unstructured":"Yuen MF, Heo J, Nahass RG, et al. Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment. J Hepatol. 2024;80(S1):S809\u201310.","journal-title":"J Hepatol"},{"key":"694_CR68","doi-asserted-by":"crossref","unstructured":"Yuen M-F, Lim Y-S, Yoon KT, et al. A phase 2 study of VIR-2218 (elebsiran) plus pegylated interferon-\u03b1 in participants with chronic hepatitis B virus infection. Lancet Gastroenterol Hepatol. 2024 (in press).","DOI":"10.1016\/S2468-1253(24)00237-1"},{"issue":"S1","key":"694_CR69","first-page":"S568","volume":"78","author":"PT Kennedy","year":"2023","unstructured":"Kennedy PT, Fung S, Buti M, et al. Efficacy and safety of siRNA JNJ-73763989, capsid assembly modulator-E (CAM-E) JNJ-56136379, and nucleos (t) ide analogs (NA) with pegylated interferon alpha-2a (PEGIFN-\u03b12a) added in immune-tolerant patients with chronic hepatitis B virus (HBV) infection: interim results from the phase 2 REEF-IT study. Hepatology. 2023;78(S1):S568\u20139.","journal-title":"Hepatology"},{"key":"694_CR70","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0168-8278(23)00509-3","volume":"78","author":"M Buti","year":"2023","unstructured":"Buti M, Heo J, Tanaka Y, et al. Pegylated interferon reduces relapses following bepirovirsen treatment in participants with chronic hepatitis b virus infection on nucleos (t) ide analogues: end of study results from the phase 2b B-Together study. Hepatology. 2023;78:S49\u201353.","journal-title":"Hepatology"},{"issue":"S1","key":"694_CR71","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/S0168-8278(24)00472-0","volume":"80","author":"K Agarwal","year":"2024","unstructured":"Agarwal K, Yuen MF, Roberts S, et al. Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone. J Hepatol. 2024;80(S1):S26\u20137.","journal-title":"J Hepatol"},{"key":"694_CR72","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/S0168-8278(24)00572-5","volume":"80","author":"S Bourgeois","year":"2024","unstructured":"Bourgeois S, Buti M, Gane EJ, et al. Efficacy, safety, tolerability, and immunogenicity of JNJ-0535 following a reduction of viral antigen levels through administration of siRNA JNJ-3989 in patients with chronic HBeAg negative hepatitis B-interim data of the OSPREY study. J Hepatol. 2024;80:S79\u201380.","journal-title":"J Hepatol"},{"issue":"S1","key":"694_CR73","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/S0168-8278(24)00471-9","volume":"80","author":"J Hou","year":"2024","unstructured":"Hou J, Xie Q, Zhang W, et al. Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA). J Hepatol. 2024;80(S1):S26.","journal-title":"J Hepatol"},{"issue":"S1","key":"694_CR74","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/S0168-8278(24)00474-4","volume":"80","author":"T Asselah","year":"2024","unstructured":"Asselah T, Fung SK, Akhan S, et al. A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos (t)ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B-Interim results of the OCTOPUS-1 study. J Hepatol. 2024;80(S1):S27\u20138.","journal-title":"J Hepatol"},{"key":"694_CR75","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/S0168-8278(23)00488-9","volume":"78","author":"EJ Gane","year":"2023","unstructured":"Gane EJ, Jucov A, Dobryanksa M, et al. Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial. J Hepatol. 2023;78:S34\u20135.","journal-title":"J Hepatol"},{"issue":"5","key":"694_CR76","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1080\/17474124.2023.2196405","volume":"17","author":"RW Hui","year":"2023","unstructured":"Hui RW, Mak LY, Seto WK, et al. Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy. Expert Rev Gastroenterol Hepatol. 2023;17(5):443\u201350.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"2","key":"694_CR77","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jhep.2024.03.022","volume":"81","author":"RH Leung","year":"2024","unstructured":"Leung RH, Hui RW, Mak LY, et al. ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B. J Hepatol. 2024;81(2):218\u201326.","journal-title":"J Hepatol"},{"issue":"1","key":"694_CR78","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jhep.2022.03.006","volume":"77","author":"K Agarwal","year":"2022","unstructured":"Agarwal K, Lok J, Carey I, et al. A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV \u201ccure.\u201d J Hepatol. 2022;77(1):245\u20138.","journal-title":"J Hepatol"},{"key":"694_CR79","doi-asserted-by":"publisher","first-page":"S807","DOI":"10.1016\/S0168-8278(24)02231-1","volume":"80","author":"T Hogan","year":"2024","unstructured":"Hogan T, Castaneda EG, Garcia EP, et al. High-dimensional analysis of flow cytometry data reveals differences in post-treatment frequencies of naive B cells, CD56dim natural killer cells, and terminally differentiated effector memory CD8+ T cells in responders versus nonresponders to bepirovirsen. J Hepatol. 2024;80:S807.","journal-title":"J Hepatol"},{"key":"694_CR80","doi-asserted-by":"publisher","first-page":"S1167","DOI":"10.1016\/S0168-8278(23)03311-1","volume":"78","author":"J Singh","year":"2023","unstructured":"Singh J, Salaun B, You S, et al. Cell-mediated immunity analysis to assess the characteristics of immune response to bepirovirsen: Examples from the B-Clear study. J Hepatol. 2023;78:S1167\u20139.","journal-title":"J Hepatol"},{"key":"694_CR81","doi-asserted-by":"publisher","first-page":"S1151","DOI":"10.1016\/S0168-8278(23)03286-5","volume":"78","author":"C Weis","year":"2023","unstructured":"Weis C, Littmann M, Triastcyn A, et al. Deep learning cluster analysis reveals subtypes in response to antisense oligonucleotide therapy in chronic hepatitis B. J Hepatol. 2023;78:S1151\u20132.","journal-title":"J Hepatol"},{"key":"694_CR82","doi-asserted-by":"publisher","first-page":"S1039","DOI":"10.1016\/S0168-8278(23)03130-6","volume":"78","author":"A Koenig","year":"2023","unstructured":"Koenig A, Bouquet J, Angelini E, et al. A primary human hepatocyte system to evaluate antisense oligonucleotide activity against clinically identified hepatitis B virus variants that contain mismatches in the bepirovirsen binding site. J Hepatol. 2023;78:S1039\u201340.","journal-title":"J Hepatol"},{"issue":"Suppl1","key":"694_CR83","first-page":"50","volume":"18","author":"RW Hui","year":"2024","unstructured":"Hui RW, Wong DK, Ho DW, et al. HBV DNA integration profiles in the natural history of chronic hepatitis B. Hep Intl. 2024;18(Suppl1):50\u20131.","journal-title":"Hep Intl"},{"key":"694_CR84","unstructured":"Tune Therapeutics. Epigenetic editing for the treatment of HBV. 2023 [cited 2024 March 7]. https:\/\/tunetx.com\/wp-content\/uploads\/2023\/12\/HEPDART_Dec5_Web.pdf"},{"issue":"31","key":"694_CR85","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.omtn.2023.02.001","volume":"14","author":"D Kostyushev","year":"2023","unstructured":"Kostyushev D, Kostyusheva A, Brezgin S, et al. Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9. Mol Ther Nucleic Acids. 2023;14(31):482\u201393.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"9","key":"694_CR86","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1016\/j.ymthe.2022.05.013","volume":"30","author":"CL Gorsuch","year":"2022","unstructured":"Gorsuch CL, Nemec P, Yu M, et al. Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo. Mol Ther J Am Soc Gene Ther. 2022;30(9):2909\u201322.","journal-title":"Mol Ther J Am Soc Gene Ther."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00694-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00694-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00694-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T22:03:08Z","timestamp":1737496988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00694-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,7]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00694-x","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,7]]},"assertion":[{"value":"24 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MF Yuen is an advisory board member and\/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. WK Seto received speaker\u2019s fees from AstraZeneca, is an advisory board member and received speaker\u2019s fees from Abbott, received research funding from Alexion Pharmaceuticals, Boehringer Ingelheim, Pfizer and Ribo Life Science, and is an advisory board member, received speaker\u2019s fees and researching funding from Gilead Sciences. LY Mak is an advisory board member of Gilead Sciences. RW Hui has no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to participate\/publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"RWHH was involved in data interpretation and drafting of the manuscript. LYM and WKS were involved in critical revision of the manuscript. MFY was involved in study concept, critical revision of the manuscript, and overall study supervision. All authors have seen and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}